Doctor Details

Camelia Lawrence, MD, FACS

Director of Breast Surgery, The Hospital of Central Connecticut and MidState Medical Center


Hartford HealthCare Medical Group


Breast Surgery < Accepting new patients for this specialty

Areas of Interest

Axilla Management, Breast Cancer Prevention, Breast Cancer Research, Breast Disease, Hidden Scar Surgery, High Risk Patients, Nipple Sparing Mastectomy, Oncologic Plastic Surgery

Physician Quicklink

Institute URL



Call for Appointment



Office Locations

  • The Cancer Institute at The Hospital of Central Connecticut

    201 North Mountain Road
    Suite 102
    Plainville, CT 06062
    Get Directions >>

    Phone: 860.224.5416
    Fax: 860.224.5406


Camelia Lawrence, MD, FACS, is a breast surgeon with the Hartford HealthCare Cancer Institute. She is a member of The Hospital of Central Connecticut’s Breast Center team.

Board-certified in surgery and fellowship-trained in advanced breast cancer surgery, she specializes in benign and malignant breast disease.

Dr. Lawrence has more than 13 years of experience in breast surgery, including reconstructive and plastic surgeries.

Before joining the Hartford HealthCare Cancer Institute, she practiced at St. Vincent’s Medical Center in Bridgeport.

She has been recognized numerous times for her work in the field of breast care, including being a 2017 “Women Leading the Way” honoree from the American Cancer Society, a 2017 “Doctor of Distinction” by the Fairfield County Business Journal; a Lynn Sage Breast Cancer Achievement Award recipient; a Susan G. Komen “More than Pink” honoree; and received the “Dr. Kenneth Woodward Memorial Award” in recognition for improving the health status of under-served patients.

She earned her medical degree from the Rochester School of Medicine and Dentistry, completed her General Surgery Residency from the Western Medical Center/New York Medical College, and (Breast) Surgical Oncology Fellowship from the John Wayne Cancer Institute.

Dr. Lawrence joins a talented team of providers including Elizabeth Riordan, MD, Leah Bassin, MD, and Katherine Del Prato, APRN. Along with fellow providers and support staff, she is dedicated to providing attentive, personalized care and guidance throughout the diagnosis and treatment of breast cancer on into survivor-ship and recovery.

Dr. Lawrence’s office is at the Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, 201 North Mountain Road, Suite 102, Plainville. To make an appointment or for more information, please call 860-224-5416.

Dr. Camilia Lawrence, Breast Surgeon at the Hartford HealthCare Cancer Institute discusses a groundbreaking study published by the New England Journal of Medicine that found women with early stage breast cancer may not need chemotherapy as a form of treatment.

Hartford HealthCare (HHC) This study sounds very promising. Tell us about the study – what were the findings?

A. The TailorX clinical trial followed over 10,000 women diagnosed with breast cancer between 2006 and 2010. Approximately 6700 women had recurrence scores between 11 and 25 which placed them in the intermediate risk group. Past research showed that women with scores between 0-10 can skip chemotherapy and those with scores greater than 25 benefited from adding chemotherapy to their hormonal regimen. The recurrence score is derived from a 21gene assay that analyzes the activity of a group of genes that can affect how a cancer is likely to behave and respond to treatment. This information helps your physician to determine how likely you will benefit from chemotherapy. The 6700 women were randomized to either receive hormonal therapy alone or hormonal therapy and chemotherapy. They were followed for nine years. The study results showed that the overall survival was about the same in both groups and there was no benefit to adding chemotherapy for most patients in the intermediate group.

HHC: How does this dovetail with what precision medicine is?

A. This study echoes the trajectory of precision medicine. It takes into account individual variability in genes and uses that information to select a treatment approach tailored specifically for that patient. It is in contrast to a one-size-fits-all approach. Moving forward many cancers will be treated in this manner –taking into consideration cancer genetic variations, environment and lifestyle of the patient.

HHC: Where is breast cancer research and treatment going…what’s next?

A. Breast cancer treatment is gravitating towards less invasive approaches. With advances in screening, early detection and patient education, we will begin to identify most cancers at it earliest stage which offers the best chance for cure. As evident by the TailorX trial, we will change our line of thinking to better understand that sometimes less is more. We now know that size may not be as critical as we once thought and that tumor biology trumps the size of the lesion. In addition with novel chemotherapeutic options, I think we will see less aggressive surgical interventions – perhaps even total elimination of complete axillary dissection and mitigation of the associated risk of chronic upper extremity lymphedema.




  • John Wayne Cancer Institute, Breast - Surgical Oncology


  • Westchester Medical Center/New York Medical College, General Surgery


  • Westchester Medical Center/New York Medical College, General Surgery

Medical School

  • Rochester School of Medicine and Dentistry 2001-2005 MD

Faculty Appointments

Quinnipiac University, Assistant Professor

The Hospital of Central Connecticut

Did you know? 

Physicians can request updates and changes made to their profile.

Request a Change